Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients

Respiratory Medicine

Volumn 108, Issue 8, 2014, Pages 1171-1179

  Dransfield, Mark T ^a,b   Feldman, Gregory ^c   Korenblat, Phillip ^d   Laforce, Craig F ^e   Locantore, Nicholas ^f   Pistolesi, Massimo ^g   Watkins, Michael L ^f   Crim, Courtney ^f   Martinez, Fernando J ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c S Carolina Pharmaceutical Research   (United States)

^d Clinical Research Center   (United States)

^e North Carolina Clinical Research   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF FLORENCE   (Italy)

^h UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chronic obstructive pulmonary disease; Head to head; Inhaled corticosteroid; Lung function

Indexed keywords

ELLIPTA; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; PLACEBO; SALBUTAMOL; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROBENZENE; DRUG COMBINATION; FLUTICASONE FUROATE; FLUTICASONE, SALMETEROL DRUG COMBINATION; GLUCOCORTICOID; VILANTEROL;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OROPHARYNX CANDIDIASIS; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THRUSH; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANDROSTADIENES; BENZYL ALCOHOLS; CHLOROBENZENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84906318083     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.05.008     Document Type: Article

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2014 Available at: http://www.goldcopd.org/uploads/users/ files/GOLD-Report-2014.pdf [Last accessed 22.01.14]
2. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 8 2007 775 789
3. G.T. Ferguson, A. Anzueto, R. Fei, A. Emmett, K. Knobil, and C. Kalberg Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Respir Med 102 8 2008 1099 1108
4. A. Sharafkhaneh, J.G. Southard, M. Goldman, T. Uryniak, and U.J. Martin Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study Respir Med 106 2 2012 257 268
5. J. Bourbeau, and S.J. Bartlett Patient adherence in COPD Thorax 63 9 2008 939 943
6. M.S. Charles, C.M. Blanchette, H. Silver, D. Lavallee, A.A. Dalal, and D. Mapel Adherence to controller therapy for chronic obstructive pulmonary disease: a review Curr Med Res Opin 26 10 2010 2421 2429
7. J. Vestbo, J.A. Anderson, P.M. Calverley, B. Celli, G.T. Ferguson, and C. Jenkins et al. Adherence to inhaled therapy, mortality and hospital admission in COPD Thorax 64 11 2009 939 943
8. K. Biggadike, R.K. Bledsoe, A.M. Hassell, B.E. Kirk, I.M. McLay, and L.M. Shewchuk et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain J Med Chem 51 12 2008 3349 3352
9. R.J. Slack, V.J. Barrett, V.S. Morrison, R.G. Sturton, A.J. Emmons, and A.J. Ford et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action J Pharmacol Exp Ther 344 1 2013 218 230
10. E.M. Kerwin, C. Scott-Wilson, L. Sanford, S. Rennard, A. Agusti, and N. Barnes et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg) on lung function in COPD Respir Med 107 4 2013 560 569
11. F.J. Martinez, J. Boscia, G. Feldman, C. Scott-Wilson, S. Kilbride, and L. Fabbri et al. Fluticasone furoate/vilanterol (100/25; 200/25 mcg) improves lung function in COPD: a randomised trial Respir Med 107 4 2013 550 559
12. M.T. Dransfield, J. Bourbeau, P.W. Jones, N.A. Hanania, D.A. Mahler, and J. Vestbo et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials Lancet Respir Med 1 2013 210 223
13. B.R. Celli, and W. MacNee Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 6 2004 932 946
14. J.L. Hankinson, J.R. Odencrantz, and K.B. Fedan Spirometric reference values from a sample of the general U.S. population Am J Respir Crit Care Med 159 1 1999 179 187
15. WMA declaration of Helsinki - ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea October 2008 [Date last updated: October 2008. Date last accessed: 20.01.14] http://www.wma.net/en/30publications/10policies/b3/index.html
16. International Conference on Harmonisation Tripartite Guideline Guidance for good clinical practice E6 (R1) 1996 http://www.ich.org/fileadmin/Public-Web- Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf [Date last accessed: 20.01.14]
17. N.A. Hanania, G. Feldman, W. Zachgo, J.-J. Shim, C. Crim, and L. Sanford et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial Chest 142 1 2012 119 127
18. J.F. Donohue Minimal clinically important differences in COPD lung function COPD 2 1 2005 111 124
19. N.S. Breekveldt-Postma, J. Koerselman, J.A. Erkens, J.W. Lammers, and R.M. Herings Enhanced persistence with tiotropium compared with other respiratory drugs in COPD Respir Med 101 7 2007 1398 1405
20. M.R. Partridge, W. Schuermann, O. Beckman, T. Persson, and T. Polanowski Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD Ther Adv Respir Dis 3 4 2009 147 157
21. M.R. Partridge, R.W. Dal Negro, and D. Olivieri Understanding patients with asthma and COPD: insights from a European study Prim Care Respir J 20 3 2011 315 323
22. C. Crim, P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, and C. Jenkins et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Eur Respir J 34 3 2009 641 647
23. P.M. O'Byrne, E.R. Bleecker, E.D. Bateman, W.W. Busse, A. Woodcock, and R. Forth et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Eur Respir J 43 3 2014 773 782
24. J. Lötvall, E.R. Bleecker, W.W. Busse, P.M. O'Byrne, A. Woodcock, and E.M. Kerwin et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial Respir Med 108 1 2014 41 49
25. P.W. Jones Health status and the spiral of decline COPD 6 1 2009 59 63